What the FDA label for Mirvaso says

The official FDA label for Mirvaso is the source of the day-29 response rates, the year-long side effect figures, and the rebound statement. Over a year of use the most common problems were flushing in about 10 out of 100 people, redness in 8, skin burning in 4, and raised eye pressure in 4. The label says redness returning worse than baseline was reported, but gives no percentage, so nobody can tell you how common it is.